top of page
Browse by category
Search


Novo Nordisk to acquire Akero Therapeutics for $4.7 billion
Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). EFX is currently in phase 3 development for the treatment of patient


Studies investigate GLP-1s promise in treating substance use disorders
There have been reports that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may also have the potential to treat alcohol and drug...


GLP-1 agonists may affect the interpretation of oncological FDG PET-CT scans
The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, according to research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25). GLP-1 receptor agonists are now widely prescribed for individuals with type 2 diabetes and weight loss, with a 700% increase in usage reported in the US between 2019 and 2023. These medications alter glucose metabolism, gastric motility and sympathetic to


High cost or insurance-related issues are the most common reasons for discontinuation with semaglutide or tirzepatide
High cost or insurance-related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for...


Metabolically active visceral fat linked to aggressive endometrial cancer
High metabolic activity of visceral fat may be associated with more aggressive endometrial cancer, according to a presentation, ‘Visceral...


Significant increase of weight loss drugs before bariatric surgery
There has been a 16-fold increase in the use of weight loss drugs among patients before metabolic and bariatric surgery, signalling an...


MBS associated with significant reductions in the rates of adverse hepatic and extrahepatic outcomes in patients with steatotic liver disease
In patients with steatotic liver disease (SLD), metabolic bariatric surgery (MBS) is associated with significant reductions in the rates...


RYGB is an effective approach for the management of obesity in selected adolescent patients
Roux-en-Y Gastric bypass (RYGB) is an effective approach for the management of obesity in selected adolescent patients, resulting in...


Endevica Bio reports co-agonism of the melanocortin-3 and -4 receptors drives robust weight loss
Endevica Bio has announced that the co-agonism of the melanocortin-3 and melanocortin-4 receptors (MC3/4R) drives robust weight loss,...


Bariatric surgery boosts short-term employment, but long-term gains uncertain
An international study led by Queensland University of Technology (QUT) researchers has found that bariatric surgery improves work...
Browse by tag






bottom of page
